Funding to Drive Nanoscale Technology for Healthcare - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Funding to Drive Nanoscale Technology for Healthcare


ePT--the Electronic Newsletter of Pharmaceutical Technology

The UK’s Technology Strategy Board has partnered with the Engineering and Physical Sciences Research Council (EPSRC) to invest as mush as £9 million ($14.2 million) in grant funding with the aim of bringing proof-of-concept ideas to pilot technology demonstration for healthcare.

The Technology Strategy Board is a UK government body sponsored by the Department for Business, Innovation, and Skills (BIS), and charged with bringing together the business community, researchers, and the public sector to meet market needs and build the future economy. The specific goal of this project is to ensure that the healthcare sector adopts emerging novel nanoscale technology-enabled solutions by providing support to a commercialization route through innovative businesses.

The focus is on highly innovative, collaborative research in nanoscale technology-enabled solutions that deliver therapeutics and diagnostics. About £3 million ($4.75 million) is available for businesses (through the Technology Strategy Board), and £6 million ($9.49 million) is available for participation by academia (through the EPSRC). Collaborations to be considered must be business-led, but draw at least one partner from large or small businesses, academia, research, and technology organizations, or not-for-profit organizations. Projects can receive between £500,000 ($791,200) and £2 million ($3.16 million).

The Technology Strategy Board will accept applications from Nov. 1, 2011 until Dec. 13, 2011. Further information can be found here.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here